News

In a recent study, taniborbactam restored in vitro activity of cefepime against Enterobacterales.

While receiving a booster of one’s original COVID-19 shot leads to an immune boost, this was heightened among individuals who received a different booster than their primary vaccine.

There are MSM who are indicated for PrEP use that don’t use it, and vice versa, the study authors found.

The FDA suggested that Johnson & Johnson had not conducted an appropriately thorough test to prove its vaccine requires a six-month booster.

New clinical trial is first to describe concomitant administration of any vaccine with either an adenoviral vector or mRNA COVID-19 vaccine.

CDI remains an urgent public health threat and continues to be the most frequent cause of diarrhea among hospitalized patients and overall hospital-acquired infection in the United States.

People who inject drugs in rural areas had a less accurate understanding of HIV PrEP, largely due to stigma surrounding sexual orientation and drug use.

Investigators found no significant difference among hospitalized patients in the ICU being administered probiotics vs placebo.

A recent study by the CDC found that HIV PrEP awareness and referrals are lower among Hispanic persons than non-Hispanic white persons.

In the recent TACKLE phase 3 trial, AZD7442 significantly reduced the risk of developing severe COVID-19 or death, even among high-risk populations.

No ICU admissions or deaths were reported among Native American patients treated with monoclonal antibodies for COVID-19 in a recent study.

The broad host range and natural reassortment of the influenza virus has played an instrumental role in previous pandemics, and the virus is poised for future large-scale outbreaks.

The filing is for the first oral antiviral therapy, and is based off its phase 3 trial.

The TakeMeHome program, a public-private partnership to distribute HIV self-test home kits to at-risk populations, is reaching at-risk individuals who weren’t otherwise accessing testing.

Providers offer their insights on this important topic.

If the FDA approves maribavir, it will be the first and only treatment for adults with CMV as a result of a hematopoietic stem cell transplant or solid organ transplant.

A global study of C. difficile isolates worldwide found a very high prevalence of the bacteria on shoe soles.

It can help inform appropriate antibiotic prescribing, but likely would only form part of testing protocol, experts say.

The HIV In-hospital Mortality Prediction (HIV-IMP) risk score showed good discrimination and calibration and may be useful in guiding clinical decision-making.

A recent study measured premature deaths among people with HIV by sex, race, and HIV risk factor.

A new study shows Medicare-aged patients being treated in hospitals saw more of these types of infections, creating a greater burden on care and costs, and showing an increased mortality rate.

The companies made the request after their recent submission of data to support the emergency use authorization (EUA) in this patient population.

Qatar has the highest mRNA vaccine coverage in the world, but their vaccinated population is experiencing significant waning in vaccine efficacy, leading to breakthrough infections.

Malaria has afflicted humanity for thousands of years, and the parasite is especially deadly for children and babies. The WHO has recommended the first malaria vaccine be deployed across sub-Saharan Africa.

This investigational therapy could be the first implantable form of PrEP.

AstraZeneca’s long-acting antibody, AZD7442, would act as a supplement to vaccination and could provide up to a year of protection against symptomatic COVID-19.

People who inject drugs are at high-risk for HIV infection, but very few are interested in PrEP prescriptions.